To this end, we demonstrate that lefamulin increases the sensitivity of sorafenib in HCC by targeting ILF3, and ILF3 could serve as a biomarker to predict the efficacy of sorafenib in HCC patients. The gene discussed is ILF3; the disease is hepatocellular carcinoma.